TGFB1 and eosinophilia-myalgia syndrome: Transforming TGF-β emerges as a central mediator: intraperitoneal TGF-β reduces NK-cell killing and downmodulates the activating receptor NKG2D (36), implicating this pathway in EMs pathogenesis.